NEW DELHI : Aurobindo Pharma Ltd posted a 45% year-on-year jump in its consolidated net profit for the January-March quarter to ₹850 crore as strong formulation sales across its markets boosted its margins.
The Hyderabad-based drugmaker’s revenue grew 16.4% at ₹6,158 crore, with sales of anti-retrovirals increasing 31% to ₹382 crore. “We have closed FY20 with a healthy performance in Q4.
The growth was seen across all our geographies. Diversified product basket has helped us to maintain the growth momentum in our core geographies like USA and Europe," managing director N.
Govindarajan said in a release. Formulation sales in the US and Europe, its two largest market, grew 20.5% and 26% respectively at ₹2,990 crore and 1,652.5 crore